The siRNA molecules will be produced in combination with Invivofectamine Rx to create a new platform intended to address human diseases with unmet medical need in China.
Ribo and Kunshan RNAi Institute CEO and founder Zicai Liang said, "Adding Life’s Invivofectamine Rx formulation technology into our development efforts will significantly increase our ability to bring new siRNA therapeutics to Chinese patients with unmet medical needs."
Under the terms of the agreement, Ribo will receive a license to develop a series of Invivofectamine Rx-based therapeutics and in exchange for each development Life Technologies will receive milestone and royalty payments.
Invivofectamine Rx uses a chemical structure to increase the potency 100-fold for use in vivo applications and to minimize the toxicity of the formulated RNAi compound.
Life Technologies chief scientific officer and global research head Alan Sachs said, "Invivofectamine Rx is a great example of the type of technology we will continue to license around the world as we expand our commitment to clinical research customers."